Mankind Pharma (MANKIND) AGM 2026 summary

Opening remarks and agenda

• The 35th AGM was conducted via audio and video conferencing, with proceedings recorded and webcast live for transparency.

• The meeting was presided over by the Executive Chairman, who acknowledged the company's 31-year journey and stakeholder contributions.

• Quorum was confirmed, directors and key managerial personnel were introduced, and statutory requirements for the meeting were outlined.

• Voting was facilitated through remote e-voting and continued for 30 minutes post-meeting; statutory documents were made available for inspection.

Financial performance review

• Consolidated revenue reached INR 14,278 crores, a 17% YoY growth; adjusted EBITDA was INR 3,629 crores with a 25.4% margin.

• Gross margin improved to 71.6%, while profit after tax declined 3.4% YoY to INR 1,938 crores due to higher depreciation and finance costs.

• Cash flow from operations was robust, with a CFO to EBITDA ratio of 89%; capex of INR 737 crores focused on manufacturing and technology upgrades.

• R&D investment increased to 2.8% of sales; net debt to adjusted EBITDA improved to 1.1x, further reduced to 0.9x after NCD repayment.

• Diluted EPS stood at INR 46.3; consumer healthcare revenue rose 9% to INR 879 crores with an 18.7% EBITDA margin.

Board and executive committee updates

• Directors, auditors, and key management were introduced; the Vice Chairman was absent due to bereavement.

• Scrutinizer for voting was appointed and attended via video conferencing.